Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11997826 | 0.98 | SLC22A2 (0.38) | SLC22A2SLC22A1SLC22A3SLC6A4FFAR4 | |
| SCHEMBL11997829 | 0.82 | FFAR4 (0.35) | FFAR4 | |
| SCHEMBL5065145 | 0.78 | ALDH1A1 (0.38) | SLC22A2SLC22A1SLC22A3SLC6A4FFAR4 | |
| SCHEMBL11997819 | 0.77 | FFAR4 (0.35) | FFAR4ALDH1A1 | |
| Bromide SCHEMBL4939222 | 0.77 | ALDH1A1 (0.41) | SLC22A2SLC22A1SLC22A3SLC6A4FFAR4 | |
| SCHEMBL11997836 | 0.69 | ADORA2A (0.40) | NPC1NTSR1RAB9AMAPK1HTT | |
| SCHEMBL1108043 | 0.65 | SLC22A2 (0.50) | SLC22A2SLC22A1SLC22A3SLC6A4CYP2E1 | |
| SCHEMBL14197386 | 0.65 | SLC22A2 (0.44) | SLC22A2SLC22A1SLC22A3SLC6A4NPC1 | |
| SCHEMBL13911034 | 0.63 | SLC22A2 (0.43) | SLC22A2SLC22A1SLC22A3SLC6A4NPC1 | |
| SCHEMBL5130299 | 0.63 | ALDH1A1 (0.69) | MAPK1KDM4EHTTALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754232-B2 | Methods of making bis-tridentate carbene complexes of ruthenium and osmium | UNIVERSAL DISPLAY CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140021453-A1 | METHODS OF MAKING BIS-TRIDENTATE CARBENE COMPLEXES OF RUTHENIUM AND OSMIUM | UNIVERSAL DISPLAY CORPORATION (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563737-B2 | Methods of making bis-tridentate carbene complexes of ruthenium and osmium | UNIVERSAL DISPLAY CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120215000-A1 | METHODS OF MAKING BIS-TRIDENTATE CARBENE COMPLEXES OF RUTHENIUM AND OSMIUM | UNIVERSAL DISPLAY CORPORATION | 2012-08-23 | — | — | US | disclosed |
| US-20120215000-A1 | METHODS OF MAKING BIS-TRIDENTATE CARBENE COMPLEXES OF RUTHENIUM AND OSMIUM | UNIVERSAL DISPLAY CORPORATION | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120215000-A1 | METHODS OF MAKING BIS-TRIDENTATE CARBENE COMPLEXES OF RUTHENIUM AND OSMIUM | OCIAD2, OCIAD1, OSTC | SLC22A2 3257/4885SLC22A1 3609/4885SLC22A3 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.